Sugi Predict

Sugi Predict / Compounds / SCHEMBL5085665

SCHEMBL5085665

SCHEMBL5085665

CCCCCCc1nc2c(c(=O)[nH]c(=O)n2C)n1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ HPGD P15428 3/20 0.56
▸ TSHR P16473 3/20 0.56
▸ HTT P42858 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ XBP1 P17861 2/20 0.55
▸ HSD17B10 Q99714 5/20 0.53
▸ POLB P06746 1/20 0.53
▸ L3MBTL1 Q9Y468 3/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ GAA P10253 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ USP2 O75604 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944694 0.94 SMN1; SMN2 (0.56) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8803669 0.94 MAPK1 (0.51) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL9392009 0.91 SMN1; SMN2 (0.53) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8952280 0.90 MAPK1 (0.48) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8802573 0.90 MAPK1 (0.51) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL315739 0.88 HSD17B10 (0.56) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8952544 0.87 GAA (0.49) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8952585 0.87 KDM4E (0.56) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL11152443 0.87 GAA (0.49) MAPK1SMN1; SMN2HPGDTSHRHTT
SCHEMBL8952581 0.87 KDM4E (0.56) MAPK1SMN1; SMN2HPGDTSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113677320-A Silk-hyaluronic acid tissue filler and methods of making and using same 自然进化公司 2021-11-19 — — CN disclosed
CN-111787920-A Pharmaceutical composition for controlling and/or reducing myopia progression 华柏恩视觉研究中心有限公司 2020-10-16 — — CN disclosed
EP-3703691-A1 PHARMACEUTICAL COMPOSITIONS FOR CONTROLLING AND/OR REDUCING THE PROGRESSION OF MYOPIA Brien Holden Vision Institute Limited (AU) 2020-09-09 — — EP disclosed
CN-111263646-A Silk-hyaluronic acid based tissue fillers and methods of use thereof 自然进化公司 2020-06-09 — — CN disclosed
WO-2008033754-A2 XANTHINE DERIVATIVES IN METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION DUKE UNIVERSITY (US) 2008-03-20 — — WO disclosed
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 — — US disclosed
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 — — EP disclosed
EP-1322184-A2 BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS THE PROCTER & GAMBLE COMPANY (US) 2003-07-02 — — EP disclosed
EP-1322185-A2 BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT THE PROCTER & GAMBLE COMPANY (US) 2003-07-02 — — EP disclosed
EP-1289532-A2 LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE The Procter & Gamble Company (US) 2003-03-12 — — EP disclosed
WO-1998030900-A2 SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA KLAUS TRIER APS (DK) 1998-07-16 — — WO disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 — — EP disclosed
WO-1992007585-A1 THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR CELLTECH LIMITED (GB) 1992-05-14 — — WO disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 — — EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 — — WO disclosed
EP-0252487-B1 PACKAGE CONTAINING DRUG COMBINATIONS FOR SUCCESSIVE ADMINISTRATION HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-08 — — EP disclosed
US-4942143-A Imidazothiadiazine derivatives, and their use as medicaments HOECHST JAPAN LIMITED (JP) 1990-07-17 — — US disclosed
EP-0286041-A1 Imidazothiadiazine derivatives, a process for preparing the same and their use as medicaments HOECHST JAPAN LIMITED (JP) 1988-10-12 — — EP disclosed
EP-0252487-A2 Package containing drug combinations for successive administration HOECHST AKTIENGESELLSCHAFT (DE) 1988-01-13 — — EP disclosed
EP-0208962-A2 Combination preparations from thrombocyte aggregation inhibitors, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-01-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA MAPK1 4513/4885SMN1; SMN2 4016/4885HPGD 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.